Akhil Anand

Akhil Anand

Auto-generated profile, based on publicly available information

Akhil Anand

Cleveland Clinic

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in General Hospital Psychiatry
Verified
Journal Article
Closed access
ACAshley Cantu-Weinstein
Ashley Cantu-Weinstein
RBRachel Branning
Rachel Branning
MAMaria Alamir
Maria Alamir
JWJeremy Weleff
Jeremy Weleff
MDMolly Do
Molly Do
AAAkhil Anand
Akhil Anand

1 June 2024 in Psychedelic Medicine
Verified
Journal Article
Closed access
BMBrian Barnett MD
Brian Barnett MD
AAAkhil Anand
Akhil Anand
EDElizabeth N. Dewey
Elizabeth N. Dewey
DSDarron Smith
Darron Smith
SNSandeep M. Nayak
Sandeep M. Nayak
JWJeremy Weleff
Jeremy Weleff
Background: Though lysergic acid diethylamide (LSD) use is rising in the United States amid expanding research into the therapeutic potential of psychedelics, little scholarly work exists on whether perceived risk of trying LSD (prLSD) is changing or factors influencing prLSD among the general public. Therefore, we sought to investigate changes in prLSD from 2015 to 2019 and identify characteristics associated with prLSD among respondents to the National Survey on Drug Use and Health (NSDUH). Methods: Using NDSUH data from 2015 to 2019, we investigated correlates of and temporal trends in prLSD, reporting results for the entire sample, as well under age 18 (<18) and age 18 and older (18+) subgroups. Orthogonal polynomial contrasts were used to evaluate trends across survey years. Multivariable models were constructed to identify factors associated with prLSD. Results: On multivariable modeling for respondents age 18+, lower prLSD had statistically significant associations with later survey year, personal LSD use, younger age, higher education level, male gender, identifying as a sexual minority, past year psychological distress, and other factors. Higher prLSD was associated with identifying as Black or Hispanic, past year suicide attempt, and having children in the home. Notable differences in the age <18 subgroup were no association between prLSD and identifying as Hispanic and male gender being associated with higher prLSD. From 2015 to 2019, there was a statistically significant linear decreasing trend in proportion of respondents who perceived “great” risk in trying LSD [from 70.5% to 64.8%; ( p < 0.0001)]. Similar trends were observed in most subgroups that were analyzed. Conclusions: We observed differences in prLSD among subgroups, suggesting that factors such as age, gender, race, ethnicity, and personal history of LSD may be related to prLSD. Overall, Americans appear to be assessing LSD's risk profile more favorably in recent years, though most Americans still perceive great risk in trying LSD.

6 January 2021 in Current Psychiatry Reports
Verified
Journal Article
Closed access
PDF file
AAAkhil Anand
Akhil Anand
AHAvinash Hosanagar
Avinash Hosanagar

1 February 2025 in Hepatology Communications
Verified
Journal Article
Open access
SSShreya Sengupta
Shreya Sengupta
AAAkhil Anand
Akhil Anand
QYQijun Yang
Qijun Yang
MRMeghan Reagan
Meghan Reagan
MHMariah Husted
Mariah Husted
JMJessica L. Mellinger
Jessica L. Mellinger
Background: We analyzed early outcomes regarding the impact of our integrated alcohol-associated liver disease (ALD) clinic on patients with ALD and alcohol use. Methods: We conducted a retrospective study of patients with ALD who were evaluated in our integrated clinic from May 1, 2022, to December 31, 2023. Primary outcomes included differences in baseline clinical/demographic data between patients who accepted versus declined an appointment and changes in the severity of ALD, alcohol consumption, functional status, hospital utilization, and remission in alcohol use disorder for evaluated patients. Results: Patients who declined appointments (n=66) had higher median no-show rates (15.0 [8.0,30.0] vs. 8.5 [3.25,15.0], p <0.001), social vulnerability index (0.53 [0.26,0.79] vs. 0.38 [0.17,0.63], p =0.033), and proportions of cirrhosis (78.8% vs. 59.8%, p =0.017) versus evaluated patients. Comparison of baseline to first follow-up visit for evaluated patients (n=102) demonstrated significant reductions in median AST (59.5 [41.75, 89] vs. 44.5 [33.5, 56.25], p <0.001), alanine-aminotransferase (33.5 [20,45.25] vs. 26.5 [18.75,33.0], p =0.017), total bilirubin (1.6 [0.7,3.3] vs. 1 [0.5,1.9], p= 0.001), phosphatidylethanol (263 [35, 784] vs. 0 [0, 163], p <0.001), MELD-3.0 and Sodium scores for patients with alcohol-associated hepatitis and cirrhosis (16 [11, 18.75] vs. 12 [9, 14], p <0.001), 14 [9.25, 17.75] vs. 11 [8.5, 14], p <0.001), and Child-Turcotte-Pugh scores for patients with cirrhosis (9 [6, 10.5] vs. 7 [6, 9], p <0.001). The proportion of patients with active-severe alcohol use disorder significantly decreased (85.2% vs. 51.9%, p <0.001). Additionally, patients had significant reductions in emergency department utilization (incidence rate ratio of 0.64 emergency department visits/month ( p =0.002) and 0.71 hospital admissions/month ( p =0.025). However, after considering the false discovery rate, the reduction in hospitalization admissions/month was not statistically significant (False Discovery Rate adjusted p =0.056). Conclusions: Our integrated approach led to reductions in liver injury, degree of liver decompensation, alcohol use, and ED utilization, and remission in AUD in a population of both non-transplant ALD and post-transplant patients.

3 February 2023 in Journal of Addiction Medicine
Verified
Journal Article
Closed access
JWJeremy Do Weleff
Jeremy Do Weleff
AKAlexsandra Kovacevich
Alexsandra Kovacevich
JBJesse Do Burson
Jesse Do Burson
NNNeil Mlis Nero
Neil Mlis Nero
AAAkhil Anand
Akhil Anand
Objectives: This systematic review aimed to identify published articles that evaluated all phenibut toxicity and withdrawal cases to understand better their clinical presentations and treatments. Methods: A comprehensive literature search was conducted using Medline (Ovid), Embase (Ovid), and Cochrane Library databases to capture all published cases on the presentations and management of phenibut toxicity or withdrawal. Results: Sixty-two cases from 36 studies on presentation and management of phenibut toxicity or phenibut withdrawal were identified. Of all subjects, 80.7% were male. The average age was 30.9 years (SD, 13.2 years; range, 0–71 years). A total of 86.8% reported obtaining phenibut online, and 63.2% reported concomitant substance use with other addictive agents; benzodiazepines and alcohol were the most combined drugs. The average length of hospital stay was 5.0 days (n = 25; SD, 5.4 days; range, 1–25 days) for phenibut toxicity and 7.7 days (n = 20; SD, 7.8 days; range, 0–30 days) for phenibut withdrawals. The most common symptoms reported during phenibut toxicity were altered mental status, somnolence, psychosis, and movement disorders. Of the phenibut toxicity cases, 48.7% required intubation. Benzodiazepines and antipsychotics were most used to treat phenibut toxicity. For phenibut withdrawal cases, 95.7% reported daily use. The most common symptoms reported during phenibut withdrawals were anxiety, irritability or agitation, insomnia, and psychosis. Sixteen (69.6%) of phenibut withdrawal cases required multiple medications for treatment. Benzodiazepines, baclofen, atypical antipsychotics, gabapentanoids, and barbiturates were commonly used to treat phenibut withdrawals. Conclusions: The seriousness of presentations, combined with the assortments of medications used for both syndromes, reflects the potential dangers of phenibut use and the need for systematized treatment protocols.

2 January 2024 in The American Journal of Drug and Alcohol Abuse
Verified
Journal Article
Closed access
GCGabriel P. A. Costa
Gabriel P. A. Costa
JNJulio C. Nunes
Julio C. Nunes
DHDaniel L Heringer
Daniel L Heringer
AAAkhil Anand
Akhil Anand
JAJoao P. De Aquino
Joao P. De Aquino
Background: The relationship between cannabis use and the risk of returning to using opioids non-medically during treatment for opioid use disorder (OUD) remains unclear.Objective: We sought to quantify the impact of cannabis use on the risk of non-medical opioid use among people receiving pharmacotherapies for OUD.Methods: A comprehensive search was performed using multiple databases from March 1 to April 5 of 2023. Eligible studies longitudinally assessed the association between cannabis use and non-medical opioid use among people with OUD receiving treatment with buprenorphine, methadone, or naltrexone. We utilized a random-effects model employing the restricted maximum likelihood method. A sensitivity analysis was conducted to understand potential differences between each OUD treatment modality.Results: A total of 10 studies were included in the final meta-analysis. There were 8,367 participants (38% female). The average follow-up time across these studies was 9.7 months (SD = 3.77), ranging from 4 to 15 months. The pharmacotherapies involved were methadone (76.3%) buprenorphine (21.3%), and naltrexone (2.4%). The pooled odds ratio did not indicate that cannabis use significantly influenced non-medical opioid use (OR: 1.00, 95% CI: 0.97-1.04, p = .98). There is evidence of moderate heterogeneity and publication bias.Conclusion: There was no significant association between cannabis use and non-medical opioid use among patients receiving pharmacotherapies for OUD. These findings neither confirm concerns about cannabis increasing non-medical opioid use during MOUD, nor do they endorse its efficacy in decreasing non-medical opioid use with MOUD. This indicates a need for individualized approaches for cannabis use and challenges the requirement of cannabis abstinence to maintain OUD pharmacotherapies.